NEWS ROUNDUP FM announces Rs 23 cr additional investment in health sector
Manipal Hospitals buys 100% stake in Vikram Hospital
Finance Minister Nirmala Sitharaman recently announced Rs 23,220 crore investment in the public health sector. Sitharaman emphasised the funding for short-term HR augmentation through medical students (interns, residents, final year) and nursing students, increase the availability of ICU beds, oxygen supply at central, district and sub-district level, adequate availability of equipment, medicines; access to teleconsultation; ambulance services and enhance testing capacity and supportive diagnostics, strengthen capacity for surveillance and genome sequencing. Besides, she announced Rs 1.1 lakh crore guarantee scheme for coronavirus affected sectors. Out of the Rs 1.1 lakh crore guarantee scheme, the healthcare sector will get Rs 50,000 lakh crore sector.
Manipal Hospitals has entered into a definitive agreement with Multiples, a private equity firm, for a 100 per cent acquisition of Bengaluru-based Vikram Hospital. The announcement comes close on the heels of its acquisition of the India operations of Columbia Asia Hospitals in April 2021. Dr Ranjan Pai, Chairman, Manipal Education and Medical Group (MEMG) said, “We are delighted to welcome Vikram Hospital into our network. Manipal Hospitals has been the top-ranked healthcare provider in Bengaluru for over two decades and this addition is a reiteration of our commitment to meet the healthcare needs of the city and the region. Two greenfield hospitals are currently under construction and once they are complete in the next 24 months, our network of 12 hospitals with over 2,300 beds would be best placed to provide ease of access and comprehensive care to everyone across this city.”
Sun Pharma signs agreement with Ferring Pharmaceuticals The wholly-owned subsidiary of Sun Pharmaceutical Industries has entered into a license agreement with Ferring Pharmaceuticals (Ferring), a subsidiary of Switzerland-based biopharmaceuticals MNC Ferring Pharmaceuticals, to commercialise a Room Temperature Stable (RTS) formulation of the obstetric drug, CARITEC (Carbetocin RTS) in India. CARITEC is indicated for the prevention of excessive bleeding in women after vaginal or caesarean childbirth. The condition is commonly known as postpartum haemorrhage (PPH).
Roche Diabetes Care appoints Omar Sherief Mohammad as Head of IMEA Roche has appointed Omar Sherief Mohammad as Head India, Middle East & Africa (IMEA) within the Roche Diabetes Care (RDC) Global Commercial Organisation, based in Mumbai. Before this appointment, Omar has been General Manager RDC
6
July 2021
Omar Sherief Mohammad, Head India, Middle East & Africa (IMEA), Roche Diabetes Care India since September 2019. Mohammad will play a key role in the shaping and executing of the overall commercial Go-To-Market Strategy, responsible for setting the strategic direction for IMEA, in alignment with the Global Commercial Organisation as well as the overall RDC strategy. In this newly created role, he will have direct oversight of IMEA and the RDC General Managers/Country Heads of these markets will directly report to him. Omar will also be General Manager in India.
NATHEALTH signs MoU with ACHE NATHEALTH-Healthcare Federation of India signed an MoU with The American College of Healthcare Executives (ACHE). Under this agreement, both federations will mutually strengthen healthcare systems by developing and providing leadership education and development experiences that will help in preparing healthcare professionals to become clinical leaders and improve patient care. The collaboration will bring in educational opportunities through inperson interactions, such as the Annual Congress on Healthcare Leadership. The partnership aims to provide a knowledgesharing platform that will enable different stakeholders to find solutions to the barriers of access to quality healthcare, ways to improve patient outcomes and attain executive positions in healthcare settings and national medical societies.
Pharma majors collaborate for clinical trial of Molnupiravir Cipla, Dr Reddy’s, Emcure, Sun Pharma and Torrent will collaborate for the clinical trial of the investigational oral anti-viral drug Molnupiravir for the treatment of mild COVID-19 in an outpatient setting in India. Between March and April this year, these five pharma companies had individually entered into a non-exclusive voluntary licensing agreement with Merck Sharpe Dohme (MSD) to manufacture and supply Molnupiravir to India and over 100 low and middle-income countries (LMICs). The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India. As per the directive of the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization, Dr Reddy’s will conduct the clinical trial using its product, and the other four pharma companies will be required to demonstrate equivalence of their product to the product used by Dr Reddy’s in its clinical trial.
